

Treatment strategies and risk of central nervous system recurrence in high-grade B-cell and Burkitt lymphoma

Authors: Dominic P Decker, MD ^{1,2}
Pamela C Egan, MD ^{1,2,3}
Adam S Zayac, MD ^{1,2,3}
Diana O Treaba, MD ^{1,4}
Adam J Olszewski, MD ^{1,2,3}

Affiliations

¹ The Warren Alpert Medical School of Brown University, Providence, RI

² Department of Medicine, Rhode Island Hospital, Providence, RI

³ Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI

⁴ Department of Pathology, Rhode Island Hospital, Providence, RI

Corresponding author: Adam J Olszewski, MD
Rhode Island Hospital
Address: 593 Eddy St
Providence, RI, 02903
Phone: (401) 444 5435
Email: adam_olszewski@brown.edu

Supplemental Table S1. Characteristics of patients with Burkitt and high-grade B-cell lymphoma

(HGBCL) included in the study.

Variable	All cases (n=64)	HGBCL (n=26)	Burkitt (n=38)	P
Age, median (IQR)	57 (45-70)	61 (50-70)	52 (39-70)	.12
Male sex, n (%)	47 (73%)	15 (58%)	32 (84%)	.024
Race: white, n (%)	56 (88%)	21 (81%)	35 (92%)	.27
HIV positive, n(%)	13 (20%)	2 (8%)	11 (29%)	.057
CD4, median (cells per mm ³)	321	241	322	.39
Performance status, n(%)				
ECOG >2	4 (6%)	1 (4%)	3 (8%)	.64
International Prognostic Index				
0-2	30 (47%)	12 (46%)	18 (47%)	.99
3-5	34 (53%)	14 (54%)	20 (53%)	
Stage, n(%)				
I/II	17 (27%)	7 (27%)	10 (26%)	.99
III/IV/unrecorded	47 (73%)	19 (73%)	28 (74%)	
Baseline involvement:				
GI tract	15 (23%)	5 (19%)	10 (26%)	.56
Bone marrow	22 (34%)	8 (31%)	14 (37%)	.79
CNS	9 (14%)	1 (4%)	8 (21%)	.071
LDH, IU median (IQR)	473 (214-1153)	271 (198-626)	610 (264-1464)	.08
First-line regimen:				
CODOX-M/IVAC ±R	13 (20%)	3 (12%)	10 (26%)	.04
Hyper-CVAD ±R	11 (17%)	1 (4%)	10 (26%)	
DA-EPOCH-R	14 (22%)	9 (35%)	5 (13%)	
R-CHOP	10 (16%)	6 (23%)	4 (11%)	
Other high-intensity ±R	8 (13%)	3 (12%)	5 (13%)	
Palliative care only	8 (13%)	4 (15%)	4 (11%)	
Intrathecal prophylaxis	44 (69%)	12 (46%)	32 (84%)	.002
Best response:				
Complete remission	40 (67%)	14 (61%)	26 (70%)	.09
Partial remission	5 (8%)	3 (13%)	2 (5%)	
Progression/early death	15 (25%)	6 (26%)	9 (25%)	